MX2018011149A - Conjugados de liberacion prolongada de analogos de exenatida. - Google Patents

Conjugados de liberacion prolongada de analogos de exenatida.

Info

Publication number
MX2018011149A
MX2018011149A MX2018011149A MX2018011149A MX2018011149A MX 2018011149 A MX2018011149 A MX 2018011149A MX 2018011149 A MX2018011149 A MX 2018011149A MX 2018011149 A MX2018011149 A MX 2018011149A MX 2018011149 A MX2018011149 A MX 2018011149A
Authority
MX
Mexico
Prior art keywords
extended release
release conjugates
conjugates
exenatide analogs
exenatide
Prior art date
Application number
MX2018011149A
Other languages
English (en)
Inventor
W Ashley Gary
V Santi Daniel
C Henise Jeffrey
l schneider Eric
Hearn Brian
Original Assignee
Prolynx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx Llc filed Critical Prolynx Llc
Publication of MX2018011149A publication Critical patent/MX2018011149A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Los conjugados de liberación prolongada de agonistas de GLP-1 estabilizados equilibran la estabilidad agonista con velocidades de liberación para proporcionar administración de larga duración para tratar diabetes y condiciones relacionadas en programas de dosificación de una vez al mes o menos frecuentes.
MX2018011149A 2016-03-16 2017-03-16 Conjugados de liberacion prolongada de analogos de exenatida. MX2018011149A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662309330P 2016-03-16 2016-03-16
US201662416058P 2016-11-01 2016-11-01
PCT/US2017/022791 WO2017161174A1 (en) 2016-03-16 2017-03-16 Extended release conjugates of exenatide analogs

Publications (1)

Publication Number Publication Date
MX2018011149A true MX2018011149A (es) 2019-05-30

Family

ID=59852218

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011149A MX2018011149A (es) 2016-03-16 2017-03-16 Conjugados de liberacion prolongada de analogos de exenatida.

Country Status (13)

Country Link
US (1) US20200164083A1 (es)
EP (2) EP3429608A4 (es)
JP (1) JP7017248B2 (es)
KR (1) KR20180129825A (es)
CN (1) CN109414469A (es)
AU (2) AU2017234680A1 (es)
BR (1) BR112018068639A2 (es)
CA (1) CA3016814A1 (es)
MX (1) MX2018011149A (es)
RU (1) RU2764547C2 (es)
SG (1) SG11201807832VA (es)
WO (1) WO2017161174A1 (es)
ZA (2) ZA201805953B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016243922A1 (en) * 2015-04-01 2017-11-02 The Scripps Research Institute Methods and compositions related to GPCR agonist polypeptides
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
JP2022544109A (ja) * 2019-08-07 2022-10-17 プロリンクス エルエルシー β脱離リンカーにより架橋したヒドロゲルの蒸気滅菌
KR102716759B1 (ko) 2023-12-20 2024-10-15 (주)인벤티지랩 엑세나타이드를 포함하는 서방형 주사제 조성물 및 이의 제조 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1143989E (pt) * 1999-01-14 2007-03-30 Amylin Pharmaceuticals Inc Exendinas para supressão de glucagon
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
RU2376314C2 (ru) * 2002-10-02 2009-12-20 Зилэнд Фарма А/С Стабилизированные соединения эксендина-4
JP4785206B2 (ja) 2005-01-14 2011-10-05 ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド 修飾されたエキセンディン（Ｅｘｅｎｄｉｎｓ）及びその使用
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN102827284B (zh) * 2006-11-14 2015-07-29 上海仁会生物制药股份有限公司 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
WO2008116294A1 (en) * 2007-03-23 2008-10-02 Matregen Corp. Exendin analogs
WO2009158668A1 (en) 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
WO2010017215A2 (en) * 2008-08-04 2010-02-11 The Regents Of The University Of California Biodegradable microspheres and methods of use thereof
KR101337322B1 (ko) * 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
DK2566335T3 (en) * 2010-05-05 2016-10-03 Prolynx Llc Controlled release of active ingredients from macromolecular CONJUGATES
WO2011140392A1 (en) * 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports
WO2011156407A2 (en) * 2010-06-09 2011-12-15 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonists to treat pancre-atitis
SG11201400444VA (en) 2011-09-07 2014-04-28 Prolynx Llc Hydrogels with biodegradable crosslinking
US20140256626A1 (en) 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide

Also Published As

Publication number Publication date
CN109414469A (zh) 2019-03-01
ZA201905787B (en) 2021-03-31
BR112018068639A2 (pt) 2019-07-30
AU2021232810A1 (en) 2021-10-14
AU2017234680A2 (en) 2018-12-13
EP3429608A4 (en) 2019-12-11
RU2018136200A (ru) 2020-04-16
JP7017248B2 (ja) 2022-02-08
AU2017234680A1 (en) 2018-10-11
SG11201807832VA (en) 2018-10-30
EP3429608A1 (en) 2019-01-23
JP2019511497A (ja) 2019-04-25
RU2764547C2 (ru) 2022-01-18
RU2018136200A3 (es) 2020-12-25
EP3922269A1 (en) 2021-12-15
WO2017161174A1 (en) 2017-09-21
ZA201805953B (en) 2019-11-27
CA3016814A1 (en) 2017-09-21
US20200164083A1 (en) 2020-05-28
KR20180129825A (ko) 2018-12-05

Similar Documents

Publication Publication Date Title
MX2018011149A (es) Conjugados de liberacion prolongada de analogos de exenatida.
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
BR112018007225A2 (pt) agonistas do receptor de glucagon
EP3922260A3 (en) Insulin receptor partial agonists and glp-1 analogues
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
DOP2017000102A (es) Coagonistas de los receptores de glucagón y de glp-1
PH12020551742A1 (en) Gip derivatives and uses thereof
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
CL2018000299A1 (es) Composiciones con potenciadores de impregnacion para el suministro de fármacos.
MX2019006260A (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad.
BR112015019985A2 (pt) Novo análogo de insulina e sua utilização
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
EA201691911A1 (ru) Быстродействующие композиции инсулина
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX361061B (es) Composicion farmaceutica liquida.
EA201391764A1 (ru) Агонисты рецептора glp-1/глюкагона длительного действия
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
MX2018008050A (es) Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.
EA201890343A1 (ru) Быстродействующие инсулиновые композиции
AR105284A1 (es) Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida